Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E PDGFRB over exp |
| Therapy | Vemurafenib |
| Indication/Tumor Type | melanoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E PDGFRB over exp | melanoma | resistant | Vemurafenib | Preclinical | Actionable | In a preclinical study, over expression of PDGFRB conferred acquired resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323). | 21107323 |
| BRAF V600E PDGFRB over exp | melanoma | resistant | Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line harboring BRAF V600E and overexpressing Pdgfrb demonstrated resistance to Zelboraf (vemurafenib) in culture (PMID: 28986383). | 28986383 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21107323) | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. | Full reference... |
| (28986383) | Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. | Full reference... |